Allena Pharmaceuticals Inc. [ALNA] fell -87.73% so far this year. What now?

Allena Pharmaceuticals Inc. [NASDAQ: ALNA] loss -30.56% on the last trading session, reaching $0.07 price per share at the time. The company report on July 19, 2022 that Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD). ALLN-346, which has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), is a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced CKD, an indication with high unmet need. ALLN-346 is a bio-engineered enzyme specifically designed to degrade urate in the gastrointestinal tract without systemic absorption and thereby reduce systemic urate levels in patients with hyperuricemia, gout and CKD.

Study 202 is a two-week, outpatient study assessing safety and tolerability in hyperuricemic patients with gout and CKD. Patients are randomized (2:1) to receive either five capsules of ALLN-346 or a matching placebo three times daily, with enrollment of up to four planned cohorts, each consisting of up to 12 patients. Cohort A has enrolled seven patients with an estimated glomerular filtration rate (eGFR) of 60-89 mL/minute (considered to have Stage 2, or mild CKD), and Cohort B has enrolled twelve patients with an eGFR of 30-59 mL/minute (considered to have Stage 3, or moderate CKD). Of note, because Study 201, a one-week inpatient study conducted at a clinical pharmacology unit, has enrolled primarily hyperuricemic patients with Stage 2 CKD, targeted enrollment of Stage 2 CKD patients in Cohort A of Study 202 was reduced from twelve to seven. Topline safety and efficacy data from cohort A and cohort B of Study 202 are expected to be available later this quarter. Pending review of the Phase 2a data and the availability of sufficient financial resources, the Company expects to open two additional cohorts later this year, consisting of gout patients with Stage 4, or advanced CKD (Cohort C) and an allopurinol combination therapy cohort in gout patients with Stage 3 CKD (Cohort D).

Allena Pharmaceuticals Inc. represents 100.62 million in outstanding shares, while the company has a total market value of $8.65 million with the latest information. ALNA stock price has been found in the range of $0.058 to $0.085.

If compared to the average trading volume of 26.13M shares, ALNA reached a trading volume of 51046638 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Allena Pharmaceuticals Inc. [ALNA]:

H.C. Wainwright have made an estimate for Allena Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 01, 2020. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Outperform. The new note on the price target was released on July 10, 2019, representing the official price target for Allena Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $20, while Robert W. Baird analysts kept a Outperform rating on ALNA stock.

The Average True Range (ATR) for Allena Pharmaceuticals Inc. is set at 0.01 The Price to Book ratio for the last quarter was 1.82, with the Price to Cash per share for the same quarter was set at 0.06.

Trading performance analysis for ALNA stock

Allena Pharmaceuticals Inc. [ALNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -33.18. With this latest performance, ALNA shares dropped by -48.07% in over the last four-week period, additionally sinking by -85.56% over the last 6 months – not to mention a drop of -93.14% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALNA stock in for the last two-week period is set at 28.92, with the RSI for the last a single of trading hit 20.59, and the three-weeks RSI is set at 34.84 for Allena Pharmaceuticals Inc. [ALNA]. The present Moving Average for the last 50 days of trading for this stock 0.1376, while it was recorded at 0.0979 for the last single week of trading, and 0.3078 for the last 200 days.

Allena Pharmaceuticals Inc. [ALNA]: A deeper dive into fundamental analysis

Return on Equity for this stock declined to -234.88, with Return on Assets sitting at -132.08.

Allena Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.

An analysis of insider ownership at Allena Pharmaceuticals Inc. [ALNA]

There are presently around $1 million, or 7.40% of ALNA stock, in the hands of institutional investors. The top three institutional holders of ALNA stocks are: TRV GP II, LLC with ownership of 2,790,964, which is approximately 0% of the company’s market cap and around 1.15% of the total institutional ownership; VANGUARD GROUP INC, holding 2,682,145 shares of the stock with an approximate value of $0.2 million in ALNA stocks shares; and ACADIAN ASSET MANAGEMENT LLC, currently with $91000.0 in ALNA stock with ownership of nearly New of the company’s market capitalization.

Positions in Allena Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 14 institutional holders increased their position in Allena Pharmaceuticals Inc. [NASDAQ:ALNA] by around 2,240,818 shares. Additionally, 11 investors decreased positions by around 932,988 shares, while 9 investors held positions by with 6,835,320 shares. The mentioned changes placed institutional holdings at 10,009,126 shares, according to the latest SEC report filing. ALNA stock had 5 new institutional investments in for a total of 1,814,030 shares, while 7 institutional investors sold positions of 250,175 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here